Clinical trial
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
NCT04509791 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 24, 2020
- Completion date
- December 16, 2024
- Enrollment
- 114 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.